Clinical Study
Safety and Feasibility of Repeated Intrathecal Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells in Patients with Neurological Diseases
Table 9
Comparison of adverse events between our study and previous studies of intrathecal non-MSCs stem cells.
| Adverse events (person-time) | Total (%)
| Our study (%)
| Literature review (%)
| |
| Headache | 114 (8.21) | 3 (2.05) | 111 (8.94) | 0.007 | Dizziness | 2 (0.14) | 2 (1.37) | 0 (0.00) | 0.011 | Fever | 114 (8.21) | 5 (3.42) | 109 (8.78) | 0.026 | Nausea | 20 (1.44) | 2 (1.37) | 18 (1.45) | 1.000 | Pain at puncture site | 32 (2.30) | 6 (4.11) | 26 (2.10) | 0.125 | Neck pain | 1 (0.07) | 1 (0.68) | 0 (0.00) | 0.105 |
|
|